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Background: There has been a growing interest in lung cancer in
never-smokers.
Methods: Utilizing a database from the National Hospital Study
Group for Lung Cancer, information for never-smokers and ever-
smokers with advanced non-small cell lung cancer was obtained
from 1990 to 2005, including clinicopathologic characteristics, che-
motherapy response, and survival data. Time of diagnosis was
classified into two periods: 1990–1999 and 2000–2005. Multivari-
ate analysis was performed using the Cox regression and logistic
regression method, including gender, age, performance status, his-
tology, stage, and period of diagnosis.
Results: There were 1499 never-smokers and 3455 ever-smokers
with advanced stage IIIB and IV diseases who received cytotoxic
chemotherapy. Never-smokers generally included more females,
were younger, with better performance status and more adenocarci-
noma diagnosed (p  0.0001 for all). Smoking status was a signif-
icant prognostic factor (never-smoker versus ever-smoker; hazard
ratio [HR] 0.880, 95% confidence interval [CI]: 0.797–0.970; p
0.0105). In separate multivariate analysis for never-smokers and
ever-smokers, female gender and better performance status (p 
0.0001 for both) were both favorable prognostic factors. However,
adenocarcinoma histology (versus squamous cell carcinoma; HR 
0.790, 95% CI: 0.630–0.990; p 0.0403) and the period after 2000
(versus before 2000; HR  0.846, 95% CI: 0.731–0.980; p 
0.0254) were significant only in the never-smokers, and younger age
(HR  1.007, 95% CI: 1.003–1.011; p  0.0010) was significant
only in the ever-smokers. In an exploratory analysis, different
profiles were observed in predictive factors for chemotherapy re-
sponse between the two groups.
Conclusions: Never-smokers with non-small cell lung cancer lived
longer than ever-smokers. Gender, histology, and time of diagnosis
are important factors for prognosis in these patients.
Key Words: Lung cancer, Never-smokers, Prognosis, Gender,
Histology.
(J Thorac Oncol. 2010;5: 1011–1017)
There has been a growing interest in lung cancer in never-smokers, and this has become an important public health
issue in Japan as well as in the United States.1,2 Global
statistics estimate that approximately 25% of lung cancer
patients are never-smokers worldwide.3 When considered as
a separate category, lung cancer in never-smokers would
constitute the seventh most common cause of cancer death
worldwide.1 Although there is no clear evidence of an in-
crease in the number of patients over time in either Japan or
the United States, this issue has gained attention partly from
the introduction of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors such as gefitinib and erlotinib.
These agents are particularly beneficial to never-smokers
with non-small cell lung cancer (NSCLC).4,5
Recent molecular epidemiological studies have con-
firmed that lung cancer arises through different molecular
mechanisms in never-smokers and ever-smokers.1,2 EGFR
mutations are associated with never-smokers and K-ras mu-
tations occur more frequently in lung cancers in ever-smok-
ers. EGFR and K-ras mutations are almost exclusively found
in adenocarcinomas,6 suggesting that lung cancer is distinct
between never-smokers and ever-smokers. Consistent with
biologic behaviors, clinical features are also clearly different
between the two groups: never-smokers with NSCLC are
mostly females and have adenocarcinoma and drastic re-
sponse to EGFR tyrosine kinase inhibitors.7 Moreover, these
patients have been reported to have a better prognosis than
ever-smokers.8–11
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Instead of a large body of work on smoking status and
survival in NSCLC, to date, there has actually been little
published data on never-smokers describing the prognostic
and predictive factors for survival and chemotherapy re-
sponse. Recently, the specific population of never-smokers
has been the focus in clinical trials. The Iressa Pan-Asia
Study (IPASS) was conducted for Asian never-smokers or
light smokers with NSCLC comparing gefitinib with carbo-
platin and paclitaxel.12
Considering this trend, identification of prognostic and
predictive factors in never-smokers will be important and
useful for clinical practice.
PATIENTS AND METHODS
Database
The National Hospital Study Group for Lung Cancer
consists of 42 National Hospital Organizations nationwide in
Japan. Data includes the institution; the time of patient
diagnoses; age; gender; World Health Organization (WHO)
performance status (PS); smoking status; histology of the
tumor; tumor, node, metastases classification; treatment type
(surgery, radiotherapy, and chemotherapy), survival time;
and prognosis including the cause of death. The chemother-
apy response is also included for the patients to receive
front-line chemotherapy. Histologic classification and assign-
ment to tumor, node, metastases classification are made based
on WHO lung cancer classification13 and the International
Staging System for Lung Cancer,14 respectively.
In this study, smoking status was categorized as ever-
smoker or never-smoker. A never-smoker was coded as a
patient who smoked less than 100 cigarettes during lifetime;
and a patient who smoked more than 100 cigarettes was
defined as an ever-smoker.
Clinical Outcome
Overall survival for each patient was measured from
the date of diagnosis to the date of death from lung cancer or
the date when the patient was last known to be alive. Data
updated on January 20, 2007, was used for this study. Ge-
fitinib was approved for use in 2002 in Japan, and median
survival time (MST) for never smokers with advanced
NSCLC was reported to be 1.37 years.9 We speculated that
the patients diagnosed after 2000 have had a chance to at least
be treated with the drug, and we separated the time periods
for analysis based on year of diagnosis into 1990–1999 and
2000–2005. Measurement of response for front-line chemo-
therapy was decided based on the WHO criteria by the
individual doctors in each hospital. Complete response (CR)
and partial response (PR) to the chemotherapy were defined
as response patients. There was no record on chemotherapy
menu in this database, and response was not confirmed by
central review. Considering these limitations, to identify
predictive factors for chemotherapy, response was performed
as an exploratory analysis.
Statistical Analysis
The differences among smoking status and other de-
mographic data were tested using the Wilcoxon rank sum
test. Variables lacking documented information were
coded as unknown and were excluded from the relevant
analyses. Survival was calculated according to the Kaplan-
Meier method. The differences in the curves were tested
using the log-rank test. Multivariate analysis for survival
and for chemotherapy response was performed using the
Cox regression method and logistic regression method.
Statistical analysis was performed using SAS 9.1.3 (SAS
Institute Inc., Cary, NC).
This study was independently approved by the institu-
tional review boards of the National Hospital Organization
Kinki-Chuo Chest Medical Center and the National Hospital
Study Group for Lung Cancer.
RESULTS
Patient Characteristics
Detailed demographic and chemotherapy response and
survival information were obtained between 1990 and 2005
through the database. A total of 4954 new cases with ad-
vanced stage IIIB or IV diseases, which received chemother-
apy without curative radiotherapy, were recorded in this
period. There were 1499 never-smokers and 3455 ever-
smokers.
Patient characteristics stratified by smoking status are
listed in Table 1. As expected, the never-smokers were more
females, younger, and had better PS and more adenocarci-
noma diagnosed (p  0.0001 for all). The distribution of the
clinical stage and the period of diagnosis were similar.
Never Smoking As a Prognostic Factor for
Survival in Patients with Advanced NSCLC
Cox analysis in the 4954 patients showed that never-
smoking status was a significant favorable prognostic factor
(versus ever-smoker; hazard ratio [HR]  0.880, 95% con-
fidence interval [CI]: 0.797–0.970; p  0.0105) as well as
female gender, younger age, better PS, adenocarcinoma his-
tology, earlier clinical stage, and recent period of diagnosis
(Table 2).
Prognostic Factors for Survival in Never-
Smokers with Advanced NSCLC
To elucidate prognosis in never-smokers and ever-
smokers with NSCLC, we calculated median overall survival
and 1-year survival estimates and then performed Cox anal-
ysis in the patients. Figures 1 and 2 show the survival of the
patients, according to smoking status, stratified by gender,
histology, and period of diagnosis, respectively. The differ-
ence in survival among the groups was statistically significant
in gender (p  0.0001 for both), histology (p  0.0001 for
both), and the period (p  0.0067 for never-smokers and p 
0.0392 for ever-smokers). Cox analysis was then performed
according to smoking status to clarify independent prognostic
factors in never-smokers with NSCLC (Table 3). Although
female gender and better PS were common significant favor-
able factors in each group, adenocarcinoma histology (versus
squamous cell carcinoma; HR  0.790, 95% CI: 0.630–
0.990; p  0.0403) and the period after 2000 (versus before
2000; HR  0.846, 95% CI: 0.731–0.980; p  0.0254) were
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significant only in the never-smokers, whereas younger age
(HR  1.007, 95% CI: 1.003–1.011; p  0.0010) was slight
but significant only in the ever-smokers.
Predictive Factors for Response to
Chemotherapy in Never-Smokers with
Advanced-Stage NSCLC
Predictive factors for response to chemotherapy were
also examined in an exploratory analysis in both never-
smokers and ever-smokers with advanced stage IIIB and IV
disease. Among never-smokers, 1275 patients were evaluable
for response to chemotherapy, including 7 CR (0.5%), 283
PR (22.2%), 672 with stable disease (SD) (52.8%), and 313
with progressive disease (PD) (24.5%). Among the 2953
patients who were ever-smokers, overall response to chemo-
therapy included 15 CR (0.5%), 700 PR (23.7%), 1410 SD
(47.7%), and 828 PD (28.1%). There was not a significant
difference in response rate between never-smokers and ever-
smokers (p  0.3197). Univariate and multivariate analysis
for response according to smoking status is shown in Table 4.
Multivariate analysis shows that response rates were higher
for the second part of the period (p  0.0001 for both) in the
two groups, whereas female gender (versus male; OR 
1.515; 95% CI: 1.139–2.016; p 0.0043), age (OR 0.999;
95% CI: 0.981–0.998; p  0.0129), and adenocarcinoma
histology (versus squamous cell carcinoma; OR  0.722,
95% CI: 0.596–0.876; p  0.0009) were significantly pre-
dictive factors only in the ever-smokers.
To provide some internal validation of chemotherapy
response, we also examined the relationship between re-
sponse rate and survival outcomes. The MST for the patients
with CR, PR, SD, and PD was 18.8, 15.1, 10.7, and 5.6
months in never-smokers, respectively, and 13.7, 12.2, 7.5,
and 4.1 months in ever-smokers, respectively. There is a
statistical significance among them (p  0.0001).
DISCUSSION
Using this large and informative database, we showed
that never-smoking status was a marginal but significant
prognostic factor in patients with advanced NSCLC com-
pared with ever-smokers. In addition, we identified prognos-
tic factors in never-smokers and demonstrated that gender
and PS were common prognostic factors regardless of smok-
ing status, and histology and time period of diagnosis were
significant only in the never-smokers, whereas age was sig-
nificant only in the ever-smokers. There was a significant
TABLE 1. Patient Characteristics for Never-Smokers and
Ever-Smokers with Advanced NSCLC
Never-Smokers Ever-Smokers p
Number 1499 (30.3) 3455 (69.7)
Median age (yr) 65 66
Gender
Female 1123 (74.9) 309 (8.9) 0.0001
Male 374 (25.0) 3143 (91.0)
Unknown 2 (0.1) 3 (0.1)
Age category (yr)
0–39 34 (2.3) 60 (1.7) 0.0001
40–49 137 (9.1) 252 (7.3)
50–59 318 (21.2) 643 (18.6)
60–69 484 (32.3) 1282 (37.2)
70–79 405 (27.0) 1044 (30.2)
80 119 (8.0) 163 (4.7)
Unknown 2 (0.1) 11 (0.3)
PS
0 365 (24.3) 696 (20.1) 0.0004
1 675 (45.0) 1734 (50.2)
2 269 (17.9) 631 (18.3)
3 123 (8.2) 274 (7.9)
4 52 (3.5) 77 (2.2)
Unknown 15 (1.0) 43 (1.3)
Histology
AD 1310 (87.4) 2068 (59.9) 0.0001
SQ 114 (7.6) 1005 (29.1)
Others 46 (3.1) 289 (8.4)
Unknown 29 (1.9) 93 (2.7)
Clinical stage
IIIB 372 (24.8) 912 (26.4) 0.2437
IV 1127 (75.2) 2543 (73.6)
Period
1990–1999 996 (66.5) 2301 (66.6) 0.8798
2000–2005 501 (33.4) 1146 (33.2)
Unknown 2 (0.1) 8 (0.2)
NSCLC, non-small cell lung cancer; PS, performance status; AD, adenocarcinoma;
SQ, squamous cell carcinoma.
TABLE 2. Cox Model for Survival for All Patients with
NSCLC (n  4954)
Hazard Ratio 95% CI p
Gender
Male 1.000
Female 0.747 0.677–0.825 0.0001
Age 1.003 1.000–1.007 0.0351
PS
0
1 1.414 1.293–1.546 0.0001
2 2.238 2.012–2.490 0.0001
3 3.479 3.047–3.973 0.0001
4 3.113 2.548–3.804 0.0001
Smoking status
Ever-smoker 1.000
Never-smoker 0.880 0.797–0.970 0.0105
Histology
SQ
AD 0.982 0.906–1.065 0.6644
Others 1.285 1.123–1.471 0.0003
Clinical stage
IIIB
IV 1.120 1.039–1.208 0.0033
Period
1990–1999 1.000
2000–2005 0.916 0.850–0.988 0.0231
NSCLC, non-small cell lung cancer; CI, confidence interval; PS, performance
status; AD, adenocarcinoma; SQ, squamous cell carcinoma.
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difference in the profile of prognostic factors between the two
groups. Our results provide additional proof to confirm that
NSCLC in never-smokers is a different disease.
There has been a large body of work that demonstrates
that never-smokers with NSCLC were more females,
younger, and had better PS and more adenocarcinoma diag-
nosed compared with ever-smokers.1,2 As expected, our study
also confirmed and solidifies these results. In prognosis, most
observational studies have demonstrated that never-smokers
had a better outcome.8 A population-based cohort study in
Southern California included a large number of patients and
provided much information.8–11 It is notable that the HR of
1.09 for survival by smoking status was almost identical to
the Japanese patients in our study. Some other studies are
unlikely to support these results15,16 possibly due to the
smaller sample sizes, but this large study detected a modest
but significant survival difference; improved survival for
NSCLC patients who are never-smokers against ever-smok-
ers is expected.
In our study, separate analysis was performed to iden-
tify prognostic factors in never-smokers with NSCLC. Gen-
der was still a common prognostic factor in both groups.
Considering smoking status in this study, enhanced potential
gender differences in advanced-stage lung cancer. Female
gender has been reported to be associated with improved
survival in cancer registry and pooled analysis from clinical
trial. Wisnivesky et al.17 reported that elderly females lived
longer than males, using a database for Surveillance, Epide-
miology, and End Results, and expected that in sensitivity
analysis, potential gender difference was not associated with
smoking status. Current study solidifies this data by direct
comparison between never-smokers and ever-smokers and is
extended in advanced stages and all ages.
Instead of the overlapping prognostic factors between
the two groups, there were significant differences in each
group. Adenocarcinoma histology was clearly associated
with improved survival in never-smokers but not in ever-
smokers. That could be explained by the EGFR mutations,
which were observed more in adenocarcinoma in never-
smokers than in ever-smokers. The tumors with EGFR mu-
tations was reported to be well differentiated18 and tend to
have less other molecular alterations,19 which is likely to be
associated with less aggressive phenotype. Moreover, the
time period after 2000 was related to favorable prognosis in
never-smokers. Again, that is possibly due to the fact that
never-smokers have more EGFR mutant tumors, which are
more active in the treatment of gefitinib. In fact, survival was
statistically unchanged in ever-smokers through the time
period based on the multivariate analysis. Takano et al.20 also
reported that patients with EGFR mutations lived longer after
the time of approval for gefitinib. In addition, in the analysis
of chemotherapy response, the odds ratio of the period was
FIGURE 1. Overall survival curves in the never-smokers with non-small cell lung cancer stratified by gender (A), histology (B),
and time period of diagnosis (C).
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TABLE 3. Cox Analysis for Never-Smokers and Ever-Smokers with Advanced NSCLC
Never-Smokers (n  1499) Ever-Smokers (n  3455)
Hazard Ratio 95% CI p Hazard Ratio 95% CI p
Gender
Male 1.000
Female 0.723 0.629–0.832 0.0001 0.769 0.669–0.883 0.0002
Age 0.998 0.992–1.003 0.4019 1.007 1.003–1.011 0.0010
PS
0 1.000 1.000
1 1.516 1.287–1.786 0.0001 1.390 1.249–1.547 0.0001
2 2.323 1.911–2.823 0.0001 2.220 1.954–2.522 0.0001
3 3.056 2.394–3.900 0.0001 3.700 3.158–4.335 0.0001
4 2.961 2.130–4.116 0.0001 3.169 2.456–4.090 0.0001
Histology
SQ
AD 0.790 0.630–0.990 0.0403 1.016 0.931–1.109 0.7204
Others 1.321 0.893–1.954 0.1630 1.290 1.117–1.491 0.0005
Clinical stage
IIIB 1.000 1.000
IV 1.228 1.063–1.419 0.0054 1.086 0.994–1.187 0.0685
Period
1990–1999 1.000 1.000
2000–2005 0.846 0.731–0.980 0.0254 0.932 0.853–1.018 0.1156
NSCLC, non-small cell lung cancer; CI, confidence interval; PS, performance status; AD, adenocarcinoma; SQ, squamous cell carcinoma.
FIGURE 2. Overall survival curves in the ever-smokers with non-small cell lung cancer stratified by gender (A), histology (B),
and time period of diagnosis (C).
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higher in never-smokers than ever-smokers. The recent reg-
imens such as carboplatin and paclitaxel, which were usually
used after 2000, may be more active in tumors with EGFR
mutations. In fact, the IPASS12 showed that higher response
was observed in EGFR-mutant positive tumors than the
negative tumors even after treatment of carboplatin and
paclitaxel.
Squamous cell carcinoma in never-smokers was ob-
served at an incidence of 8% in this study. This population
was relatively small, but the clinical feature is of interest.
Although there is no significant difference of survival for the
patients with squamous cell carcinoma between never-smok-
ers and ever-smokers (data not shown), the MST and 1-year
survival rates are numerically lower in the never-smokers.
The cause of squamous cell carcinoma in the never-smokers
has been unknown to date. Passive smoking is likely to affect
development of the tumor.21 Human papillomavirus may also
be associated with this tumor, particularly in Asia.22 Further
research will be required.
Another interesting finding in this study is that age did
not influence prognosis in never-smokers but it did in ever-
smokers. Younger patients lived slightly and significantly
longer than the ever-smokers. That is partly explained by the
fact that cardiovascular and chronic obstructive diseases oc-
curred with age and affect prognosis, which is common in
ever-smokers. On the other hand, older never-smokers tend to
have more EGFR mutations. In the IPASS, 68.5% of the
patients who were positive for EGFR mutations were more
than 65 years old and 56.7% were less than 65 years old.12
Again, EGFR mutations are associated with less aggressive
phenotypes of cancer.
Chemotherapy response was examined in an explor-
atory analysis in this study. Our information was limited to
the front-line chemotherapy, and the effect of gefitinib was
not included in the analysis, which was used in more than
second-line treatment. The response rates were similar be-
tween never-smokers and ever-smokers (22.2% and 23.7%,
respectively, p  0.3197). One retrospective study showed
that no difference was seen in response rate between ever-
smokers and never-smokers receiving a wide variety of cy-
totoxic chemotherapy drugs,23 and another study showed
significant difference between them.9 There is still contro-
versy over whether smoking status affects response to cyto-
toxic drugs, and chemotherapy regimens and ethnicity may
be considered as well. Compared with 32.2% in the IPASS,12
the current response rates are lower in the never-smokers.
That is partly due to the period before 2000 included in the
analysis. In fact, the response rate in never-smokers was
33.8% when analyzing the patients between 2000 and 2005.
Higher response rates were observed in the second part of the
time period in the two groups; however, there was still a
difference between them for gender, age, and histology.
Female gender, younger age, and squamous cell carcinoma
histology were associated with higher response only in ever-
TABLE 4. Univariate and Multivariate Analysis for Response Rate (CR  PR) in Never-Smokers and
Ever-Smokers
Never-Smokers (n  1275) Ever-Smokers (n  2953)
Response Rate (%) 95% CI p Response Rate (%) 95% CI p
Gender
Male 20.2 15.7–24.7 23.6 22.0–25.2
Female 23.8 21.0–26.6 0.1947 31.0 25.2–36.8 .0099
Histology
SQ 26.0 17.1–34.9 27.2 24.2–30.2
AD 22.6 20.1–25.1 0.6380 22.2 20.3–24.2 .0086
Others 19.1 6.0–32.1 27.6 21.9–33.3
Period
1990–1999 17.0 14.4–19.6 0.0001 20.6 18.8–22.4 .0001
2000–2005 33.8 29.3–38.3 31.4 28.4–34.3
Odds Ratio 95% CI p Odds Ratio 95% CI p
Gender
Male 1.000 1.000
Female 1.325 0.952–1.842 0.0949 1.515 1.139–2.016 0.0043
Age 0.992 0.980–1.004 0.1979 0.989 0.981–0.998 0.0129
Histology
SQ 1.000 1.000
AD 0.791 0.486–1.289 0.3471 0.722 0.596–0.876 0.0009
Others 0.730 0.293–1.819 0.4995 1.003 0.730–1.379 0.9854
Period
1990–1999 1.000 1.000
2000–2005 2.644 2.008–3.481 0.0001 1.825 1.527–2.180 0.0001
CI, confidence interval; CR, complete response; PR, partial response; AD, adenocarcinoma; SQ, squamous cell carcinoma.
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smokers. Again, these results may support the idea that the
tumors in never-smokers have different biologic behavior.
Several strengths and limitations in this study should be
noted. An advantage of our study is the inclusion of a large
sample size of about 5000, which strengthens statistical
significance. In addition, the data was collected nationwide
and was multi-institutional based, and important and useful
information was available, including smoking status and PS.
On the other hand, a limitation is lack of information
for EGFR status in tumors, where mutations are observed at
approximately 60% in never-smokers.24 However, this is not
always examined routinely for clinical practice. Lung cancer
in never-smokers is still heterogeneous biologically, and a
large database including molecular markers such as EGFR
status will be valuable.
Another problem is the different and diffuse chemo-
therapy menu used, which may influence prognosis of the
patients but was not recorded in this database. Despite no
uniform treatment algorithm, standard chemotherapy seems
to have been given in the hospitals at the relevant time, and
the drugs were randomly distributed among subgroups with-
out taking into consideration smoking status.
In conclusion, this large study demonstrates that never-
smokers with NSCLC lived longer than ever-smokers and
that gender, histology, and time of diagnosis are important
factors for prognosis in never-smokers. Different profiles of
prognostic factors will enhance the idea that NSCLC in
never-smokers should be treated as a distinctive disease.
Smoking status should be incorporated into clinical trial
design as well as decision-making processes for NSCLC
treatment. Lung cancer in never-smokers is still heteroge-
neous, and further research to clarify its molecular and
biologic features is warranted.
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